2026-01-20 - Analysis Report
**Merck Stock Analysis Report**

## Company Overview
Merck is a multinational pharmaceutical, healthcare and life science company.

## Return Rate Comparison
### Provided Data
- Ticker: MRK
- Cumulative Return: 25.67%
- Divergence from S&P 500 (VOO): -68.63% (simply the difference in cumulative return on the last day of the data)

### Comparison Analysis
The cumulative return of Merck (25.67%) is lower than that of S&P 500 (93.30%). This indicates a significant divergence, suggesting the need for further evaluation to determine if Merck's performance is lagging behind the broader market.

## Alpha and Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | 24.0% | 14.7% | 20.0% | 0.7  | 182.1B |
| 2017-2019  | 37.0% | 14.7% | 19.0% | 0.7  | 216.8B |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7  | 195.0B |
| 2019-2021  | 0.0%  | 19.3% | -43.0% | 0.6  | 191.4B |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5  | 277.1B |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3  | 272.3B |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3  | 248.5B |
| 2023-2025  | -24.0% | 39.0% | -86.0% | 0.3  | 262.9B |

## Recent Stock Price Fluctuations
- Close: $108.83
- 5-day SMA: $109.65
- 20-day SMA: $107.19
- 60-day SMA: $98.44
- Price fluctuation issue: The stock price has recently experienced a sharp decline (sharp rebound, -1.93% change).

## RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence
- Market Risk Indicator (MRI): 0.80
- RSI: 56.63
- PPO: -0.18
- Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium (MRI 0.80)
- Recent (20 days) relative divergence change: -1.00 (-): worsening
- 7-day Rank change: 70 (+): rank up
- 7-day Dynamic Expected Return change: 1.00 (+): improving
- Expected Return: -29.60%

## Recent News & Significant Events
- [2026-01-15] Is Merck Stock A Trap At $110? - Forbes (link)
- [2026-01-19] Is Merck (MRK) Pricing Reflect Long Term Value After Recent Share ... - Yahoo Finance (link)
- [2026-01-19] Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF MERCK & CO. INC. ... - Quiver Quantitative (link)
- [2026-01-19] 3 “Forever Stocks” to Hold When the Market Won’t Sit Still - MarketBeat (link)
- [2026-01-15] What’s In Store For Merck Stock? - Trefis (link)
- [2026-01-16] Is Merck (MRK) Pricing In Its Recent Share Run Or Leaving Further Upside? - simplywall.st (link)

## Analyst Opinions
```text
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 113.48 / 135.00 / 83.00
```

## Recent Earnings Analysis
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

## Financial Information
### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

## Comprehensive Analysis (Summary of previous items)
Merck's stock performance is lagging behind the S&P 500, with a cumulative return of 25.67% compared to 93.30%. The company's financial information shows strong revenue and profit margins, along with a stable capital structure. Analysts have a buy consensus with an average target price of $113.48. However, the recent price fluctuation and decline in expected return indicate a need for caution. The overall market risk is medium, while the hybrid signal suggests buying with a cash allocation of 0%.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.